2,000
Participants
Start Date
August 1, 2025
Primary Completion Date
August 1, 2030
Study Completion Date
August 1, 2030
Observational
The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively
University Hospital Cologne, Cologne
GELLC (Grupo Español de Leucemia Linfocítica Crónica)
OTHER
Nordic Lymphoma Group
NETWORK
Polish Adult Leukemia Group
OTHER
HOVON - Dutch Haemato-Oncology Association
OTHER
German CLL Study Group
OTHER